Biased, wrong and counterfeited evidences published during the COVID-19 pandemic, a systematic review of retracted COVID-19 papers

被引：15
作者：
Capodici A. [1 ,2 ]
Salussolia A. [1 ]
Sanmarchi F. [1 ]
Gori D. [1 ]
Golinelli D. [1 ]
机构：
[1] Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum - Università di Bologna, Via San Giacomo 12, Bologna
[2] Department of Medicine (Biomedical Informatics), Stanford University - School of Medicine, Stanford, CA
来源：
Quality & Quantity | 2023年 / 57卷 / 5期
关键词：
COVID-19; Frauds; Misconduct; Peer-review; Retracted; Systematic review;
D O I：
10.1007/s11135-022-01587-3
中图分类号：
学科分类号：
摘要：
In 2020 COVID-19 led to an unprecedented stream of papers being submitted to journals. Scientists and physicians all around the globe were in need for information about this new disease. In this climate, many articles were accepted after extremely fast peer-reviews to provide the scientific community with the latest discoveries and knowledge. Unfortunately, this also led to articles retraction due to authors’ misconduct or errors in methodology and/or conclusions. The aim of this study is to investigate the number and characteristics of retracted papers, and to explore the main causes that led to retraction. We conducted a systematic review on retracted articles, using PubMed as data source. Our inclusion criteria were the following: English-language retracted articles that reported original data, results, opinions or hypotheses on COVID-19 and Sars-CoV-2. Twenty-seven retracted articles were identified, mainly reporting observational studies and opinion pieces. Many articles published during the first year of the pandemic have been retracted, mainly due to the authors' scientific misconduct. Duplications, plagiarism, frauds and absence of consent, were the main reasons for retractions. In modern medicine, researchers are required to publish frequently, and, especially during situations like the COVID-19 pandemic, when articles were rapidly published, gaps in peer-reviews system and in the path to scientific publication arose. © 2022, The Author(s), under exclusive licence to Springer Nature B.V.
引用
收藏
页码：4881 / 4913
页数：32
相关论文
共 96 条
[51]  
Kampf G., Analyzing pre-pandemic patterns of contacts is partly inappropriate to explain the current COVID-19 situation in Germany, Lancet Reg Health Eur, 12, (2022)
[52]  
Khalifa N.E.M., Taha M.H.N., Manogaran G., Loey M., A deep learning model and machine learning methods for the classification of potential coronavirus treatments on a single human cell, J. Nanopart. Res, 22, 11, (2020)
[53]  
Kory P., Meduri G.U., Iglesias J., Varon J., Marik P.E., Clinical and scientific rationale for the "MATH+" hospital treatment protocol for COVID-19, J. Intensive Care Med, 36, 2, pp. 135-156, (2021)
[54]  
Lin S.L., Intersectionality and inequalities in medical risk for severe COVID-19 in the Canadian Longitudinal study on aging, Gerontologist, 61, 5, (2021)
[55]  
Lincoln M., Gabr A., Kennedy C., Et al., Collaboration, supervision and patient safety in the era of COVID-19: an analysis of medical wards and ICU, Ir. J. Med. Sci., 191, 3, pp. 1085-1087, (2022)
[56]  
Liu Y., Jiang T.T., Shi T.Y., Liu Y.N., Liu X.M., Xu G.J., Li F.L., Wang Y.L., Wu X.Y., WITHDRAWN: The effectiveness of diaphragmatic breathing relaxation training for improving sleep quality among nursing staff during the COVID-19 outbreak: A before and after study, Sleep Med X, 2, (2020)
[57]  
Lu X., Zhang M., Qian A., Tang L., Xu S., Lung ultrasound score in establishing the timing of intubation in COVID-19 interstitial pneumonia: A preliminary retrospective observational study, Plos One, 15, 9, (2020)
[58]  
Ma R., Wu H., Deng Z., Identify and measure the degree of over-prevention behaviors in the post-COVID-19 era in China, BMC Public Health, 21, 1, (2021)
[59]  
Mao K., WITHDRAWN: Health risk assessment and health management of urban residents facing epidemic pneumonia, Work, 70, 2, pp. 673-674, (2021)
[60]  
Mehra M.R., Desai S.S., Ruschitzka F., Patel A.N., RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis, Lancet, 22, (2020)
12345678910